Whilst SMARCA2 inhibition has been demonstrated as a successful therapeutic strategy in SMARCA4-deficient cancer cell lines, its viability is yet to be confirmed in brain cancer cell lines where SMARCA4 is frequently inactivated. This evidence concerns the gene SMARCA2 and brain cancer.